ProCE Banner Activity


The New Array of Choices in Prostate Cancer—What’s Best for Your Patients? Part 2

Podcast Episodes

Prostate cancer is the most frequently diagnosed cancer in men in the United States and the second leading cause of cancer mortality in this group. In recent years, a range of new and emerging therapeutic agents offer new options for healthcare providers and their patients across the continuum of this disease. This second of 2 podcasts offers an overview of current strategies and best approaches in treatment selection and adverse event management for patients with prostate cancer, as well as expert case discussion with Rana McKay, MD, Arjun Balar, MD, and Terran Simms, MSN, ACNP-C, CNN-BC, COCN.

To access episode 1, click here.

Physician Assistants: maximum of 0.50 hours of AAPA Category 1 CME credits Registered Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacology credit

Released: February 10, 2022

Expiration: February 09, 2023

No longer available for credit.



Arjun Balar

Arjun Balar, MD

Associate Professor of Medicine
Division of Hematology/Oncology
NYU Langone Health
New York, New York

Rana R. McKay

Rana R. McKay, MD

Associate Professor
Department of Medicine
Divisions of Hematology/Oncology and Urology
University of California San Diego
San Diego, California

Terran W. Sims

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Nurse Practitioner
Department of Urology
University of Virginia
Charlottesville, Virginia


This program is cosupported by educational grants from Astellas and Pfizer; Bayer HealthCare Pharmaceuticals Inc.; and Seagen Inc.

This activity is supported by educational grants from Astellas and Pfizer and Bayer HealthCare Pharmaceuticals Inc.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize available and emerging agents across the continuum of prostate cancer

  • Apply efficacy and safety evidence, molecular testing, and guideline recommendations to develop treatment plans for patients with prostate cancer

  • Implement strategies to identify and manage adverse events associated with treatment of prostate cancer


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.

Dr McKay: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Merck, Myovant, Novartis, Pfizer, Sanofi, Sorrento Therapeutics, and Tempus.

Ms Sims: consulting fees: Coloplast.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. Listen to the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the post-test and evaluation form

The estimated time to complete this activity is 0.50 hours.

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 67%.

Release date: February 10, 2022
Expiration date: February 9, 2023




The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until February 9, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA Course Advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.